Anúncio
Mercado fechado
  • BOVESPA

    122.331,39
    -305,57 (-0,25%)
     
  • MERVAL

    38.390,84
    +233,89 (+0,61%)
     
  • MXX

    52.604,05
    +91,14 (+0,17%)
     
  • PETROLEO CRU

    80,89
    +0,06 (+0,07%)
     
  • OURO

    2.332,40
    +1,60 (+0,07%)
     
  • Bitcoin USD

    61.929,33
    +1.668,75 (+2,77%)
     
  • CMC Crypto 200

    1.283,84
    +34,72 (+2,78%)
     
  • S&P500

    5.469,30
    +21,43 (+0,39%)
     
  • DOW JONES

    39.112,16
    -299,05 (-0,76%)
     
  • FTSE

    8.247,79
    -33,76 (-0,41%)
     
  • HANG SENG

    18.072,90
    +45,19 (+0,25%)
     
  • NIKKEI

    39.418,00
    +244,85 (+0,63%)
     
  • NASDAQ

    19.995,25
    +23,00 (+0,12%)
     
  • BATS 1000 Index

    0,0000
    0,0000 (0,00%)
     
  • EURO/R$

    5,8471
    +0,0020 (+0,03%)
     

Heard on the Street: Moderna Got a Boost From Bird Flu, but Don’t Count Your Chicks

Heard on the Street: Moderna Got a Boost From Bird Flu, but Don’t Count Your Chicks

Moderna, BioNTech, CureVac and Novavax have added billions of dollars in combined market capitalization gains in recent days after two cases of bird flu were reported in humans in the U.S. and reports emerged of a potential federal government vaccine program. On Wednesday, Moderna gained 14% while BioNTech added 11%. CureVac jumped 19%.